Skip to main content

Cardiovascular Disease Prevention: Pharmacologic Prevention.

Publication ,  Journal Article
Reamy, BV; Viera, AJ
Published in: FP Essent
September 2022

Several drugs have shown benefits in primary and secondary prevention of cardiovascular disease (CVD). Aspirin should be used routinely for the secondary prevention of CVD. Low-dose aspirin should not be used for the primary prevention of CVD in adults ages 60 years and older. Aspirin can be considered for primary prevention in adults ages 40 to 59 years with a 10% or greater 10-year CVD risk. Moderate- to high-intensity statin therapy should be prescribed for most patients with known atherosclerotic CVD, those with a low-density lipoprotein (LDL) cholesterol level of 190 mg/dL or higher, and those ages 40 to 75 years with diabetes or with a 10-year risk of CVD of 7.5% or greater. Newer lipid-lowering drugs have shown benefits in lowering LDL cholesterol levels, but at high cost and with limited evidence of reduction of CVD outcomes. Polypills provide a method to deliver multiple proven drugs at lower cost and to a broader population. Sodium-dependent glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists should be added to metformin as the preferred second-line drug in the management of diabetes because of their proven ability to improve cardiovascular outcomes. No supplements have proven benefits in CVD prevention. Omega-3 fatty acids and folic acid have shown benefits when consumed in food.

Duke Scholars

Published In

FP Essent

ISSN

2159-3000

Publication Date

September 2022

Volume

520

Start / End Page

20 / 25

Location

United States

Related Subject Headings

  • Middle Aged
  • Humans
  • Diabetes Mellitus, Type 2
  • Cholesterol, LDL
  • Cardiovascular Diseases
  • Aspirin
  • Aged
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reamy, B. V., & Viera, A. J. (2022). Cardiovascular Disease Prevention: Pharmacologic Prevention. FP Essent, 520, 20–25.
Reamy, Brian V., and Anthony J. Viera. “Cardiovascular Disease Prevention: Pharmacologic Prevention.FP Essent 520 (September 2022): 20–25.
Reamy BV, Viera AJ. Cardiovascular Disease Prevention: Pharmacologic Prevention. FP Essent. 2022 Sep;520:20–5.
Reamy, Brian V., and Anthony J. Viera. “Cardiovascular Disease Prevention: Pharmacologic Prevention.FP Essent, vol. 520, Sept. 2022, pp. 20–25.
Reamy BV, Viera AJ. Cardiovascular Disease Prevention: Pharmacologic Prevention. FP Essent. 2022 Sep;520:20–25.

Published In

FP Essent

ISSN

2159-3000

Publication Date

September 2022

Volume

520

Start / End Page

20 / 25

Location

United States

Related Subject Headings

  • Middle Aged
  • Humans
  • Diabetes Mellitus, Type 2
  • Cholesterol, LDL
  • Cardiovascular Diseases
  • Aspirin
  • Aged
  • Adult